Download MendeleyAn in vitro experimental pipeline to characterize the epitope of a SARS-CoV-2 neutralizing antibody.
Atanasoff, K.E., Brambilla, L., Adelsberg, D.C., Kowdle, S., Stevens, C.S., Slamanig, S., Hung, C.T., Fu, Y., Lim, R., Tran, L., Allen, R., Sun, W., Duty, J.A., Bajic, G., Lee, B., Tortorella, D.(2024) mBio 15: e0247723-e0247723
- PubMed: 38054729
- DOI: https://doi.org/10.1128/mbio.02477-23
- Primary Citation of Related Structures:
8EQF - PubMed Abstract:
The COVID-19 pandemic remains a significant public health concern for the global population; the development and characterization of therapeutics, especially ones that are broadly effective, will continue to be essential as severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) variants emerge. Neutralizing monoclonal antibodies remain an effective therapeutic strategy to prevent virus infection and spread so long as they recognize and interact with circulating variants. The epitope and binding specificity of a neutralizing anti-SARS-CoV-2 Spike receptor-binding domain antibody clone against many SARS-CoV-2 variants of concern were characterized by generating antibody-resistant virions coupled with cryo-EM structural analysis and VSV-spike neutralization studies. This workflow can serve to predict the efficacy of antibody therapeutics against emerging variants and inform the design of therapeutics and vaccines.
Organizational Affiliation:
Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
